Effects of propofol on human hepatic microsomal cytochrome P450 activities

Xenobiotica

Volumn 28, Issue 9, 1998, Pages 845-853

  Mckillop, D ^a   Wild, M J ^a   Butters, C J ^a   Simcock, C ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; ANESTHETIC AGENT; CYTOCHROME P450; DEXTROMETHORPHAN; FURAFYLLINE; KETOCONAZOLE; OXYGENASE; PHENACETIN O DEETHYLASE; PROPOFOL; QUINIDINE; SULFAPHENAZOLE; TESTOSTERONE; TOLBUTAMIDE;

ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; HUMAN; HUMAN TISSUE; INTRAVENOUS ANESTHESIA; LIVER MICROSOME;

ANESTHETICS, INTRAVENOUS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; OXIDOREDUCTASES, O-DEMETHYLATING; PROPOFOL; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

EID: 0031669251     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982598239092     Document Type: Article

References (24)

1. BAILIE, G. R., COCKSHOTT, I. D., DOUGLAS, E. J. and BOWLES, B. J. M., 1992, Pharmacokinetics of propofol during and after long term continuous infusion for maintenance of sedation in ICU patients. British Journal of Anaesthesia, 68, 486-491.
2. BAKER, M. T., CHADAM, M. V. and RONNENBERG, W. C. Jr, 1993, Inhibitory effects of propofol on cytochrome P450 activities in rat hepatic microsomes. Anesthesia and Analgesia, 76, 817-821.
3. BERTZ, R. J. and GRANNEMAN, G. R., 1997, Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clinical Pharmacokinetics, 32, 210-258.
4. CHEN, T. L., UENG, T. H., CHEN, S. H., LEE, P. H., FAN, S. Z. and LIU, C. C., 1995a, Human cytochrome P450 mono-oxygenase system is suppressed by propofol. British Journal of Anaesthesia, 74, 558-562.
5. CHEN, T. L., WANG, M. J., HUANG, C. H., LIU, C. C. and UENG, T. H., 1995b, Differences between in vivo and in vitro effects of propofol on defluorination and metabolic activities of hamster hepatic cytochrome P450 mono-oxygenases. British Journal of Anaesthesia, 75, 462-466.
6. GEPTS, E., CAMU, F., COCKSHOTT, I. D. and DOUGLAS, E. J., 1987, Disposition of propofol administered as constant rate intravenous infusion in humans. Anesthesia and Analgesia, 66, 1256-1263.
7. GEPTS, E. JONCKHEER, K, MAES, V, SONCK, W and CAMU, F., 1988, Disposition kinetics of propofol during alfentanil anaesthesia. Anaesthesia, 43 (suppl.), 8-13.
8. JANICKI, P. K., JAMES, M. F. M. and ERSKINE, W. A. R., 1992, Propofol inhibits enzymatic degradation of alfentanil and sufentanil by isolated liver microsomes in vitro. British Journal of Anaesthesia, 68, 311-312.
9. KHARASCH, E. D. and THUMMEL, K., 1993, Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance ? Anesthesia and Analgesia, 76, 1033-1039.
10. KRONBACH, T., FISCHER, V. and MEVER, U. A., 1988, Cyclosporine metabolism in human liver: Identification of a cytochrome P450IIIA gene family as the major cyclosporine-metabolising enzyme explains interactions of cyclosporine with other drugs. Clinical Pharmacology and Therapeutics, 43, 630-635.
11. LABROO, R. B., THUMMEL, K. E., KUNZE, K. L., PODOLL, T., TRAGER, W. F. and KHARASCH, E. D., 1995, Catalytic role of cytochrome P450 3A4 in multiple pathways of alfentanil metabolism. Drug Metabolism and Disposition, 23, 490-496.
12. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. and RANDALL, R. J., 1951, Protein measurement with the folin phenol reagent. Journal of Biological Chemistry, 193, 165-175.
13. MAITRE, P. O., VOZEH, S., HEYKANTS, J., THOMSON, D. A. and STANSKI, D. R., 1987, Population pharmacokinetics of alfentanil: the average dose-plasma concentration relationship and interindividual variability in patients. Anesthesiology, 66, 13-16.
14. MCKILLOP, D., 1985, Effects of phenobarbitone and β-naphthoflavone on hepatic microsomal drug metabolising enzymes of the male beagle dog. Biochemical Pharmacology, 34, 3137-3142.
15. NELSON, D. R., KAMATAKI, T., WAXMAN, D. J., GUENGERICH, F. P., ESTABROOK, R. W., FEYEREISEN, R., GONZALEZ, F. J., COON, M. J., GUNSALUS, I. C., GOTOH, O., OKUDA, K. and NEBERT, D. W., 1993, The P450 superfamily: Update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA and Cell Biology, 12, 1-51.
16. PERTEK, J. P., CHAOUI, K., JUNKE, E., ARTIS, M., COISSARD, A., FRISONI, A. and MEISTELMAN, C., 1996, Effets du propofol sur les concentrations sanguines de ciclosporine. Annales Francaises d'Anesthesie et de Reanimation, 15, 589-594 (English abstract).
17. RING, B. J., BINKLEY, S. N., VANDENBRANDEN, M. and WRIGHTON, S. A., 1996, In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A British Journal of Clinical Pharmacology, 41, 181-186.
18. SERVIN, F., DESMONTS, J. M., HABERER, J. P., COCKSHOTT, I. D., PLUMMER, G. F. and FARINOTTI, R., 1988, Pharmacokinetics and protein binding of propofol in patients with cirrhosis. Anesthesiology, 69, 887-891.
19. 14C-propofol. Xenobiotica, 18, 429-440.
20. 14C-propofol. Xenobiotica, 21, 1325-1335.
21. SPATZENEGGER, M. and JAEGER, W., 1995, Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metabolism Reviews, 27, 397-417.
22. VON MOLTKE, L. L., GREENBLATT, D. J., DUAN, S. X., HARMATZ, J. S. and SHADER, R. I., 1994a, In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. Journal of Clinical Pharmacology, 34, 1222-1227.
23. VON MOLTKE, L. L., GREENBLATT, D. J., COTREAU-BIBBO, M. M., HARMATZ, J. S. and SHADER, R. I., 1994b, Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. British Journal of Clinical Pharmacology, 38, 23-31.
24. VON MOLTKE, L. L., GREENBLATT, D. J., COTREAU-BIBBO, M. M., DUAN, S. X., HARMATZ, J. S. and SHADER, R. I., 1994c, Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. Journal of Pharmacology and Experimental Therapeutics, 268, 1278-1283.